Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A.
Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment from Lead-in Cohort in Phase 2 HCV Study Enrollment in Phase 3 SUNRISE-3 Study Has Surpassed 1,400 COVID-19.
BOSTON, Feb. 21, 2024 Atea Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases,.
BOSTON, Jan. 03, 2024 Atea Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases,.